Herophilus
Herophilus develops therapies for complex brain diseases by using human-specific brain models to discover targets and drug candidates with improved translational potential. The company cultures patient stem cell–derived brain organoids at scale using automation and scaled-biology platforms to run high-throughput, AI-driven phenotypic screens that capture molecular, cellular, and tissue-level deep phenotypes. Advanced data analytics and machine learning integrate high-dimensional imaging and molecular readouts to identify disease mechanisms and prioritize therapeutic candidates. Herophilus operates as a neurotherapeutics drug discovery and development company serving biotechnology and pharmaceutical partners.
Herophilus
Herophilus develops therapies for complex brain diseases by using human-specific brain models to discover targets and drug candidates with improved translational potential. The company cultures patient stem cell–derived brain organoids at scale using automation and scaled-biology platforms to run high-throughput, AI-driven phenotypic screens that capture molecular, cellular, and tissue-level deep phenotypes. Advanced data analytics and machine learning integrate high-dimensional imaging and molecular readouts to identify disease mechanisms and prioritize therapeutic candidates. Herophilus operates as a neurotherapeutics drug discovery and development company serving biotechnology and pharmaceutical partners.
TL;DR
Focus: Neuro drug discovery using patient stem cell–derived brain organoids, scaled biology, and machine learning to generate high‑dimensional deep phenotypes.
Founded: 2017
Headquarters: 1405 Minnesota Street, San Francisco, CA 94107, United States
Notable financing: $16.0M reported Jan 5, 2021; investors include KF Ventures and Luxor Capital Group.
Company Overview
Problem Domain
Complex brain diseases (neurotherapeutics discovery for conditions such as Rett syndrome, Alzheimer’s disease, and schizophrenia).
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
16000000
The Jan 5, 2021 round is reported at $16.0M; some records label the round as Series A while others list it as Seed. Reported investors for this round include KF Ventures, Luxor Capital Group, Kinled Holding, and 515 Ventures.
Seed round announced on 2017-03-31; amount not available in provided excerpts.
Investor Signal
“Reported investors include KF Ventures, Luxor Capital Group, Kinled Holding, 515 Ventures, and Liquid 2 Ventures.”